Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Sarcoma Research
Published in: Clinical Sarcoma Research 1/2016

Open Access 01-12-2016 | Case report

Pazopanib: a novel treatment option for aggressive fibromatosis

Authors: Gulcan Bulut, Anil Ozluk, Atike Pınar Erdogan, Ruchan Uslu, Nevra Elmas, Burcak Karaca

Published in: Clinical Sarcoma Research | Issue 1/2016

Login to get access

Abstract

Background

Aggressive fibromatosis (AF), also known as desmoid tumor, is an uncommon soft tissue neoplasm. AF does not metastasize, but it is locally invasive and its propensity for recurrence after conservative resection is well documented. No effective cytotoxic treatment has been reported, hence there is a need for novel treatment strategies.

Case presentation

We present the case of an AF successfully treated with an oral tyrosine kinase inhibitor, pazopanib, with mild side effects. As far as we know, this is the first case of AF with complete response to pazopanib.

Conclusion

Pazopanib might be an effective treatment option for AF.
Literature
1.
Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6(2):98–101.CrossRefPubMed
2.
Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G, Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100(3):612–20.CrossRefPubMed
3.
Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24(7):1195–203.CrossRefPubMed
4.
Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, Jimenez M, Duffaud F, Piperno-Neumann S, Mignot L, Blay JY. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol. 2011;22(2):452–7.CrossRefPubMed
5.
Martin-Liberal J, Benson C, McCarty H, Thway K, Messiou C, Judson I. Pazopanib is an active treatment in desmoid tumor/aggressive fibromatosis. Clin Sarcoma Res. 2013;3(1):13.CrossRefPubMedPubMedCentral
6.
Gounder MM, Lefkowitz RA, Keohan ML, D’Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG. Activity of sorafenib against desmoid tumor/aggressive fibromatosis. Clin Cancer Res. 2011;17(12):4082–90.CrossRefPubMedPubMedCentral
7.
Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol. 2012;23(3):562–9.CrossRefPubMed
8.
Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. Accessed 27 Jan 2014.
9.
VOTRIENT (pazopanib hydrochloride) tablet, film coated (Glaxo Smith Kline LLC). DailyMed. 2013.
10.
Braschi-Amirfarzan M, Abhishek R, et al. Role of imaging in management of desmoid-type fibromatosis: a primer for radiologists. Radiographics. 2016;36(3):767–82.CrossRefPubMed
11.
Jo JC, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs. 2014;32(2):369–76.CrossRefPubMed
12.
Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, Gronchi A, Bertario L, Pierotti MA, Pilotti S. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res. 2007;13(17):5034–40.CrossRefPubMed
13.
Martin-Liberal J, Judson I, Benson C. Anti angiogenic approach in soft-tissue sarcomas. Expert Rev Anticancer Ther. 2013;13(8):975–82.CrossRefPubMed
14.
Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE); a randomized, double-blind, placebo controlled phase 3 trial. Lancet. 2012;379(9829):1879–86.CrossRefPubMed
Metadata
Title
Pazopanib: a novel treatment option for aggressive fibromatosis
Authors
Gulcan Bulut
Anil Ozluk
Atike Pınar Erdogan
Ruchan Uslu
Nevra Elmas
Burcak Karaca
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Clinical Sarcoma Research / Issue 1/2016
Electronic ISSN: 2045-3329
DOI
https://doi.org/10.1186/s13569-016-0061-3

Other articles of this Issue 1/2016

Clinical Sarcoma Research 1/2016 Go to the issue

Case report

Primary intraosseous meningioma: an osteosclerotic bone tumour mimicking malignancy

Research

High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas

Case Report

Primary Kaposi’s sarcoma of the nasal cavity: a case report and review of the literature

Research

Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours

Case report

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

Case report

Metastatic meningioma presenting as a malignant soft tissue tumour
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits